当前位置: X-MOL 学术Support. Care Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study.
Supportive Care in Cancer ( IF 3.1 ) Pub Date : 2019-07-06 , DOI: 10.1007/s00520-019-04938-3
Angélique Saint 1 , J Viotti 2 , D Borchiellini 1 , B Hoch 3 , V Raimondi 4 , C Hebert 1 , R Largillier 3 , L Evesque 1 , P Follana 1 , J M Ferrero 1 , C Delaby 5 , R Schiappa 2 , E Chamorey 2 , J Barriere 1, 6
Affiliation  

PURPOSE Anemia is common in oncology and negatively impacts quality of life. However, there is lack of knowledge about iron deficiency (ID) epidemiology. The aim of this study was to prospectively assess iron status in patients with locally advanced or metastatic cancer beginning chemotherapy. METHODS In this prospective, multicenter cohort study, anemia and ID were evaluated in patients with locally advanced or metastatic solid tumors and lymphoma before starting chemotherapy. Blood samples were collected at inclusion (W0), 6 weeks (W6), and 12 weeks (W12). Prevalence was evaluated in the general population, according to tumor location and was correlated with tumor response. RESULTS One hundred twenty-nine patients were enrolled between 2013 and 2015; 119 had solid tumors and 10 lymphomas. At W0, there were no significant difference between locations with a prevalence around 50-60% (range 47.2-70.4%) and only a trend for colorectal cancer (70.4%, P = 0.069) due to a higher prevalence of absolute ID (18.5%). Prevalence of ID+ decreased between W0 and W6 and remained stable until W12 due to the proportion of patients with ID and without anemia. However, anemia prevalence increased during W0 and W6 and remained stable to W6 from W12 due to patients with anemia but without ID. A significant correlation between tumor response and ID prevalence was found (P = 0.036). CONCLUSIONS We confirm the high prevalence of ID and anemia in cancer patients. ID status is correlated to tumor response providing a strong rationale for iron monitoring during cancer management.

中文翻译:

一线化疗期间转移性癌症中的铁缺乏症:一项前瞻性流行病学研究。

目的贫血在肿瘤科中很常见,会对生活质量产生负面影响。但是,缺乏有关铁缺乏症(ID)流行病学的知识。这项研究的目的是前瞻性评估开始化疗的局部晚期或转移性癌症患者的铁状态。方法在这项前瞻性,多中心队列研究中,在开始化疗之前对患有局部晚期或转移性实体瘤和淋巴瘤的患者进行了贫血和ID评估。在入选(W0),6周(W6)和12周(W12)收集血液样本。根据肿瘤的位置评估普通人群的患病率,并将其与肿瘤反应相关。结果2013年至2015年共招募129例患者。119例患有实体瘤,10例淋巴瘤。在W0,由于绝对ID的患病率较高(18.5%),患病率在50-60%(范围47.2-70.4%)附近的人群之间无显着差异,而结直肠癌的趋势仅为70.4%(P = 0.069)。由于有ID和无贫血的患者比例,ID +的患病率在W0和W6之间下降,直到第12周保持稳定。但是,由于有贫血但没有ID的患者,在W0和W6期间贫血患病率增加,从W12到W6保持稳定。发现肿瘤反应与ID患病率之间存在显着相关性(P = 0.036)。结论我们证实癌症患者中ID和贫血的患病率很高。ID状态与肿瘤反应相关,为癌症治疗期间铁监测提供了有力的依据。由于绝对ID的发生率较高(18.5%),大肠癌仅占4%)(70.4%,P = 0.069)。由于有ID和无贫血的患者比例,ID +的患病率在W0和W6之间下降,直到第12周保持稳定。但是,由于有贫血但没有ID的患者,在W0和W6期间贫血患病率增加,从W12到W6保持稳定。发现肿瘤反应与ID患病率之间存在显着相关性(P = 0.036)。结论我们证实癌症患者中ID和贫血的患病率很高。ID状态与肿瘤反应相关,为癌症治疗期间铁监测提供了有力的依据。由于绝对ID的发生率较高(18.5%),大肠癌仅占4%)(70.4%,P = 0.069)。由于有ID和无贫血的患者比例,ID +的患病率在W0和W6之间下降,直到第12周保持稳定。但是,由于有贫血但没有ID的患者,在W0和W6期间贫血患病率增加,从W12到W6保持稳定。发现肿瘤反应与ID患病率之间存在显着相关性(P = 0.036)。结论我们证实癌症患者中ID和贫血的患病率很高。ID状态与肿瘤反应相关,为癌症治疗期间铁监测提供了有力的依据。由于有ID和无贫血的患者比例,ID +的患病率在W0和W6之间下降,直到第12周保持稳定。但是,由于有贫血但没有ID的患者,在W0和W6期间贫血患病率增加,从W12到W6保持稳定。发现肿瘤反应与ID患病率之间存在显着相关性(P = 0.036)。结论我们证实癌症患者中ID和贫血的患病率很高。ID状态与肿瘤反应相关,为癌症治疗期间铁监测提供了有力的依据。由于有ID和无贫血的患者比例,ID +的患病率在W0和W6之间下降,直到第12周保持稳定。但是,由于有贫血但没有ID的患者,在W0和W6期间贫血患病率增加,从W12到W6保持稳定。发现肿瘤反应与ID患病率之间存在显着相关性(P = 0.036)。结论我们证实癌症患者中ID和贫血的患病率很高。ID状态与肿瘤反应相关,为癌症治疗期间铁监测提供了有力的依据。结论我们证实癌症患者中ID和贫血的患病率很高。ID状态与肿瘤反应相关,为癌症治疗期间铁监测提供了有力的依据。结论我们证实癌症患者中ID和贫血的患病率很高。ID状态与肿瘤反应相关,为癌症治疗期间铁监测提供了有力的依据。
更新日期:2020-02-23
down
wechat
bug